Scientific Publications & Presentations

Scientific Publications & Presentations

TiNivo: Tivozanib Combined With Nivolumab: Safety and Efficacy in Patients With Metastatic Renal Cell Carcinoma (mRCC)
Authors: Philippe Barthelemy, Bernard J. Escudier, Alain Ravaud, Sylvie Negrier, Michael N. Needle, Laurence Albiges Hôpitaux Universitaires de Strasbourg, Strasbourg, France; Institut Gustave Roussy and Université Paris-Saclay, Villejuif, France; Hôpital Saint-André, CHU de Bordeaux, Bordeaux, France; Centre Léon-Bérard, Lyon, France; AVEO Oncology, Cambridge, MA, USA; Institut Gustave Roussy, Université Paris Sud, Villejuif, France Click here for link to article.
Randomized, Phase II Study of FiclatuzumabWith or Without Cetuximabin PatientsWith Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Authors: Julie E. Bauman, SimranSindhu, Denise Roe, Nabil F. Saba, Jessica R. Bauman, Christine H. Chung, Jessica L. Geiger, AartiBhatia, Steven Wang, Audrey Baker, Shethal Bearelly, Carlos Caulin, Protul Shrikant, Barbara Burtness, and Panayiotis Savvides Click here for link to article.
Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial
Authors: Robert J. Motzer, Dmitry Nosov, Timothy Eisen, Igor Bondarenko, Vladimir Lesovoy, Oleg Lipatov, Piotr Tomczak, Oleksiy Lyulko, Anna Alyasova, Mihai Harza, Mikhail Kogan, Boris Y. Alekseev, Cora N. Sternberg, Cezary Szczylik, David Cella, Cristina Ivanescu, Andrew Krivoshik, Andrew Strahs, Brooke Esteves, Anna erkenblit, Thomas E. Hutson Click here for link to article.
Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study
Authors: Ana M. Molina a, Thomas E. Hutson b, Dmitry Nosov c, Piotr Tomczak d, Oleg Lipatov e, Cora N. Sternberg f, Robert Motzer g, Tim Eisen h Click here for link to article.
Tan - Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC
Authors: Eng-Huat Tan, Wan-Teck Lim, Myung-Ju Ahn, Quan-Sing Ng, Jin Seok Ahn, Daniel Shao-Weng Tan, Jong-Mu Sun, MayHan, Francis C. Payumo, Krista McKee, Wei Yin, Marc Credi, Shefali Agarwal, Jaroslaw Jac, and Keunchil Park Click here for link to article.
Mok – Ph2 Combo Fic and Gefitinib in Asian Pts with Pulmonary Adenocarcinoma
Authors: Tony Shu Kam Mok, MD'Correspondence information about the author MD Tony Shu Kam MokEmail the author MD Tony Shu Kam Mok, Sarayut Lucien Geater, MD, Wu-Chou Su, MD, Eng-Huat Tan, M.B.B.S., James Chi-Hsin Yang, MD, PhD, Gee-Chen Chang, MD, May Han, PhD, Philip Komarnitsky, MD, PhD, MBA, Francis Payumo, ScM, Jennifer E. Garrus, PhD, Sandra Close, PhD, Keunchil Park, MD, PhD Click here for link to article.
Prrx1 isoform switching regulates pancreatic cancer invasion and metastatic colonization
Authors: Shigetsugu Takano,1,2,3,4 Maximilian Reichert,1,2,3,5 Basil Bakir,1,2,3 Koushik K. Das,1,2,3 Takahiro Nishida,4 Masaru Miyazaki,4 Steffen Heeg,1,2,3,6 Meredith A. Collins,1,2,3 Benoît Marchand,1,2,3 Philip D. Hicks,1,2,3 Anirban Maitra,7,8 and Anil K. Rustgi1,2,3,9. Click here for link to article. Click here for link to Supplemental Text and Figures.
Antitumor Activity and Safety of Tivozanib (AV-951) in a Phase II Randomized Discontinuation Trial in Patients With Renal Cell Carcinoma
Authors: Nosov D, Esteves B, Lipatov O, Lyulko A, Anischenko A, Chacko R, Doval D, Strahs A, Slichenmyer W, and Bhargava P JCO May 10, 2012:1678-1685; DOI:10.1200/JCO.2011.35.3524. Click here for link to article.
Biological and Clinical Activity of Tivozanib, a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4 Week on, 2 Week off Schedule in Patients With Advanced Solid Tumors.
Authors: Eskens FALM, de Jonge MJA, Bhargava P, Isoe T, Cotreau MM, Esteves B, Hayashi K, Burger H, Thomeer M, van Doorn L, Verweij J.
Clin Cancer Res. 10.1158/1078-0432.CCR-11-0411. (October 5, 2011). Click here for link to article.

Development of second-generation VEGFR tyrosine kinase inhibitors: Current status
Authors: Bhargava P, Robinson MO.
Curr Oncol Rep. 2011. doi:10.1007/s11912-011-0154-3. Click here for link to article.

GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling
Authors: Bai A, Meetze K, Vo NY, Kollipara S, Mazsa EK, Winston WM, Weiler S, Poling LL, Chen T, Ismail NS, Jiang J, Lerner L, Gyuris J, Weng Z.
Cancer Res. 2010 Oct 1;70(19):7630-9. Epub 2010 Aug 13. Click here for link to article.

Non-germline genetically engineered mouse models for translational cancer research
Authors: Joerg Heyer, Lawrence N. Kwong, Scott W. Lowe and Lynda Chin
Nature Reviews Cancer, July 2010, vol. 10, no. 7, 470-80. Click here for article.

Chimeric mouse tumor models reveal differences in pathway activation between ERBB family- and KRAS-dependent lung adenocarcinomas.
Authors: Yinghui Zhou, William M. Rideout 3rd, Tong Zi, Angela Bressel, Shialaja Reddypalli, Rebecca Rancourt, Jin K. Woo, James W. Horner, Lynda Chin, M. Isabel Chiu, Marcus Bosenberg, Tyler Jacks, Steven C. Clark, Ronald A. Depinho, Murray O. Robinson, and Joerg Heyer.
Nat Biotechnol. 2010 Jan;28(1):71-8. Epub 2009 Dec 20

Human-in-mouse breast cancer model
Authors: Min Wu and Murray O. Robinson
Cell Cycle 2009, vol. 8, 2317-18. Click here for article.

Dissecting genetic requirements of human breast tumorigenesis in a tissue transgenic model of human breast cancer in mice
Authors: Min Wu, Lina Jung, Adrian B. Coopers, Christina Fleet, Lihao Chen, Lyne Breault, Kimberly Clark, Zhuau Cai, Sylvie Vincent, Steve Bottega, Qiong Shen, Andrea Richardson, Marcus Bosenburg, Stephen P. Naber, Ronald A. DePinho, Charlotte Kuperwasser, and Murray O. Robinson
Proc Natl Acad Sci U S A. 2009, vol.106, 7022-27. Click here for article. 

Cancer Drug Discovery and Development: The Oncogenomics Handbook
Edited by W. J. LaRochelle and R. A. Shimkets © Humana Press Inc., April 2005.
Genetically Engineered Mouse Models of Human Cancer for Drug Discovery and Development (Chapter 16)
Authors: Ronan C. O'Hagan, Min Wu, William M. Rideout III, Yinghui Zhou and Joerg Heyer
Essential role for oncogenic Ras in tumour maintenance
Chin L, Tam A, Pomerantz J, Wong M, Holash J, Bardeesy N, Shen Q, O'Hagan R, Pantginis J, Zhou H, Horner JW 2nd, Cordon-Cardo C, Yancopoulos GD, DePinho RA.
Nature. 1999 Jul 29; 400(6743): 468-72.